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Background. Children in Guinea-Bissau receive measles vaccine (MV) at 9 months of age, but studies have shown that an ad-
ditional dose before 9 months of age might have beneﬁcial nonspeciﬁc effects. Within a randomized trial designed to examine non-
speciﬁc effects of early MV receipt on mortality, we conducted a substudy to investigate the effect of early MV receipt on morbidity.
Methods. Children were randomly assigned at a ratio of 2:1 to receive 2 doses of MV at 18 weeks and age 9 months (intervention
group) or 1 dose of MV at age 9 months, in accordance with current practice (control group). Children were visited weekly from
enrollment to age 9 months; the mother reported morbidity, and the ﬁeld assistants examined the children. Using Cox and binomial
regression models, we compared the 2 randomization groups.
Results. Among the 1592 children, early measles vaccination was not associated with a higher risk of the well-known adverse
events of fever, rash, and convulsions within the ﬁrst 14 days. From 15 days after randomization to age 9 months, early measles
vaccination was associated with reductions in maternally reported diarrhea (hazard ratio [HR], 0.89; 95% conﬁdence interval
[CI], .82–.97), vomiting (HR, 0.86; 95% CI, .75–.98), and fever (HR, 0.93; 95% CI, .87–1.00).
Conclusion. Early MV receipt was associated with reduced general morbidity in the following months, supporting that early MV
receipt may improve the general health of children.
Keywords. measles vaccine; adverse events; morbidity; non-speciﬁc effects of vaccines; heterologous immunity; pediatric.
Vaccines are designed to induce immunity to speciﬁc diseases,
but research has shown that vaccines may yield so-called non-
speciﬁc effects (NSEs) involving altered susceptibility to a vari-
ety of infectious diseases other than those targeted by the
vaccine. Live vaccines, such as measles vaccine (MV) and oral
polio vaccine (OPV), may have beneﬁcial NSEs and reduce
overall mortality beyond what is expected from protection
against their target diseases [1–4]. In contrast, inactivated vac-
cines, such as diphtheria-tetanus-pertussis (DTP) vaccine, de-
spite providing protection against the target diseases, have
been associated with increased overall mortality [5, 6].
The beneﬁcial NSEs of MV have been tested in a randomized
trial in Guinea-Bissau. In low-income countries, the World
Health Organization (WHO) recommends receiving MV at 9
months of age. This guideline is a compromise between avoid-
ing interference with maternal antibodies, which reduce the an-
tibody response to MV, and minimizing the risk of acquiring
early measles virus infection [7]. The Bandim Health Project
(BHP) in Guinea-Bissau conducted a randomized trial (during
2003–2007) to test the NSEs of early MV receipt [1]. Children
aged 4.5 months were enrolled and followed until 36 months of
age. The intervention group received 2 doses of MV (an early
dose at 4.5 months of age and the recommended dose at 9
months of age). The control group received only the recom-
mended dose at 9 months of age. The study showed a 22% re-
duction (95% conﬁdence interval [CI], −5%–41%) in mortality
before 36 months of age in the intervention group, in the inten-
tion-to-treat analysis. Many children had also been enrolled in a
trial of neonatal vitamin A supplementation (NVAS); among
children not receiving NVAS at birth, early MV receipt was as-
sociated with a 41% reduction (95% CI, 11%–61%) in mortality
between 4.5 and 36 months of age; in children who had received
NVAS, the effect of MV receipt was a 7% higher (95% CI,
−29%–61%) mortality risk [1]. The effect of early MV receipt
was also seen for hospital admission, in which early MV receipt
was associated with a signiﬁcant reduction in all-cause hospital-
izations between 4.5 and 9 months of age [8]. This was
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speciﬁc effects (NSEs) involving altered susceptibility to a vari-
ety of infectious diseases other than those targeted by the
vaccine. Live vaccines, such as measles vaccine (MV) and oral
polio vaccine (OPV), may have beneﬁcial NSEs and reduce
overall mortality beyond what is expected from protection
against their target diseases [1–4]. In contrast, inactivated vac-
cines, such as diphtheria-tetanus-pertussis (DTP) vaccine, de-
spite providing protection against the target diseases, have
been associated with increased overall mortality [5, 6].
The beneﬁcial NSEs of MV have been tested in a randomized
trial in Guinea-Bissau. In low-income countries, the World
Health Organization (WHO) recommends receiving MV at 9
months of age. This guideline is a co promise between avoid-
ing interference with maternal antibodies, which reduce the an-
tibody response to MV, and minimizing the risk of acquiring
early measles virus infection [7]. The Bandim Health Project
(BHP) in Guinea-Bissau conducted a randomized trial (during
2003–2007) to test the NSEs of early MV receipt [1]. Children
aged 4.5 months were enrolled and followed until 36 months of
age. The intervention group received 2 doses of MV (an early
dose at 4.5 months of age and the recommended dose at 9
months of age). The control group received only the recom-
ended dose at 9 months of age. The study showed a 22% re-
duction (95% conﬁdence interval [CI], −5%–41%) in mortality
before 36 months of age in the intervention group, in the inten-
tion-to-treat analysis. Many children had also been enrolled in a
trial of neonatal vitamin A supplementation (NVAS); among
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sociated with a 41% reduction (95% CI, 11%–61%) in mortality
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consistent with ﬁndings of another study, which indicated that
MV reduced non–measles-related mortality among hospitalized
children in Guinea-Bissau [9].
We do not know whether early MV receipt also affects the
incidence of less serious morbidities for which children are
not hospitalized. In 2011, when children no longer received
NVAS, the BHP initiated a randomized trial examining the ef-
fect of 2 doses of MV at 18 weeks and 9 months of age (inter-
vention) versus 1 dose of MV at 9 months of age (control). A
substudy was initiated to test whether early MV receipt reduced
general morbidity up to 9 months of age, when all children re-
ceived MV. We also investigated adverse events in connection
with early MV receipt. The results from the substudy are pre-
sented in the present article.
METHODS
Setting and Study Population
The BHP in Guinea-Bissau maintains a health and demograph-
ic surveillance system in the capital, Bissau. The study area cov-
ers 6 districts with around 100 000 inhabitants. Three health
centers in the study area provide routine vaccinations, and
BHP registers all vaccines given to children living in the study
area. A ﬁeld team visits all houses once monthly to record new
pregnancies and births.
Main Trial Design
The main trial was initiated in August 2011. Children were ran-
domly assigned to receive either 2 doses of MV at 18 weeks and
9 months of age (the intervention group) or the recommended
single dose of MV at 9 months of age (the control group). The
BHP identiﬁed all newborn children in the study area and re-
minded the mothers to bring their children for vaccination at
the health centers. Children in Guinea-Bissau receive pentava-
lent vaccine (targeting DTP, hepatitis B, andHaemophilus inﬂu-
enzae type b infection) at 6, 10, and 14 weeks of age [10].
Children between 18 weeks and 7 months of age, who had re-
ceived the third and last dose of pentavalent vaccine at least 4
weeks earlier, were eligible to be enrolled in the trial. NVAS
was not given during the study. There were no reports of circu-
lating measles virus during the trial; the last measles epidemic in
Bissau was in 2003–2004.
When the child was ready to be enrolled, the mother/guard-
ian was invited to come to the health center. At the health cen-
ter, the mother/guardian received an explanation of the study in
the local language, Creole, and a written explanation in the of-
ﬁcial language, Portuguese. Anthropometric measurements of
the child were performed, and a clinical examination conducted
by a physician. Provided the mother agreed to participate, she
was asked to sign or ﬁngerprint a consent form. The mother
then drew a numbered lot from an envelope to randomly assign
the child to the intervention or control group, using block ran-
domization stratiﬁed by sex (block size, 24; randomization ratio,
2:1 for the intervention group to the control group). The vaccine
used was a standard-titer Edmonston-Zagreb MV from the
Serum Institute of India. Placebo was not used, as mothers
may erroneously believe that their child received MV and not
seek MV when their child reached 9 months of age. Children
with physical malformations or with severe malnutrition
(mid-upper-arm circumference, <115 mm) were excluded and
referred for treatment. Overtly sick children were not invited
to participate but, instead, were referred to consultation at the
health center; the mother and her child were invited back for
enrollment once the child had recovered.
Morbidity Substudy Design
The substudy of morbidity was initiated in October 2011, and
the last child was enrolled in June 2013. For logistic reasons, a
maximum of 5 children were enrolled every day; if >5 children
were eligible, the 5 youngest were selected. Children enrolled in
the substudy were followed with weekly morbidity interviews
between enrollment and 9 months of age. Trained ﬁeld assis-
tants who were unaware of the child′s randomization status
conducted interviews with the mother. The ﬁrst weekly visit
with a child took place 6 days after enrollment, and the ﬁeld as-
sistant would explain the purpose and the procedures of the
weekly visits. To give the mother a better understanding of
the symptoms, we gave them a ﬂyer with custom-made illustra-
tions of the symptoms. At the weekly visits, the ﬁeld assistants
asked about the following symptoms during each of the past 7
days (with the day of visit included): diarrhea, vomiting, cough,
lack of appetite, crying more than usual, fever, and convulsions.
Furthermore, the assistant asked whether the mother had taken
the child for consultation or given the child medicine. If any
medication was administered during the past 7 days, the mother
was asked to show the medication, and the type of medication
was recorded. In addition to the interview, on the day of the visit
the assistant registered whether skin reactions, conjunctivitis,
and nasal discharge were present and measured the child’s ax-
illary temperature. If the ﬁeld assistant encountered a sick child,
the child was referred for consultation. If a child had moved
within the BHP catchment area, the ﬁeld assistant would imme-
diately try to visit the new house. Follow-up for a child would
terminate if the child moved outside the study area.
Deﬁnition of Possible Adverse Events
Adverse events associated with MV were deﬁned as fever, con-
vulsions, and skin reactions. Fever may occur around days 5–12
after MV receipt, and the risk of febrile seizures increases
around day 8–14 [11]. Fever was deﬁned as an axillary temper-
ature of >37.0°C. MV-associated adverse events affecting the
skin were deﬁned as generalized exanthema, which occurs
around day 7–10 after vaccination [11]. To have a period in
which most adverse events would be captured, we analyzed ad-
verse events from days 5 to 14.
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Vaccines are designed to induce immunity to speciﬁc diseases,
but research has shown that vaccines may yield so-called non-
speciﬁc effects (NSEs) involving altered susceptibility to a vari-
ety of infectious diseases other than those targeted by the
vaccine. Live vaccines, such as measles vaccine (MV) and oral
polio vaccine (OPV), may have beneﬁcial NSEs and reduce
overall mortality beyond what is expected from protection
against their target diseases [1–4]. In contrast, inactivated vac-
cines, such as diphtheria-tetanus-pertussis (DTP) vaccine, de-
spite providing protection against the target diseases, have
been associated with increased overall mortality [5, 6].
The beneﬁcial NSEs of MV have been tested in a randomized
trial in Guinea-Bissau. In low-income countries, the World
Health Organization (WHO) recommends receiving MV at 9
months of age. This guideline is a compromise between avoid-
ing interference with maternal antibodies, which reduce the an-
tibody response to MV, and minimizing the risk of acquiring
early measles virus infection [7]. The Bandim Health Project
(BHP) in Guinea-Bissau conducted a randomized trial (during
2003–2007) to test the NSEs of early MV receipt [1]. Children
aged 4.5 months were enrolled and followed until 36 months of
age. The intervention group received 2 doses of MV (an early
dose at 4.5 months of age and the recommended dose at 9
months of age). The control group received only the recom-
mended dose at 9 months of age. The study showed a 22% re-
duction (95% conﬁdence interval [CI], −5%–41%) in mortality
before 36 months of age in the intervention group, in the inten-
tion-to-treat analysis. Many children had also been enrolled in a
trial of neonatal vitamin A supplementation (NVAS); among
children not receiving NVAS at birth, early MV receipt was as-
sociated with a 41% reduction (95% CI, 11%–61%) in mortality
between 4.5 and 36 months of age; in children who had received
NVAS, the effect of MV receipt was a 7% higher (95% CI,
−29%–61%) mortality risk [1]. The effect of early MV receipt
was also seen for hospital admission, in which early MV receipt
was associated with a signiﬁcant reduction in all-cause hospital-
izations between 4.5 and 9 months of age [8]. This was
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ety of infectious diseases other than those targeted by the
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overall mortality beyond what is expected from protection
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cines, such as diphtheria-tetanus-pertussis (DTP) vaccine, de-
spite providing protection against the target diseases, have
been associated with increased overall mortality [5, 6].
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ing interference with maternal antibodies, which reduce the an-
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dose at 4.5 months of age and the recommended dose at 9
months of age). The control group received only the recom-
ended dose at 9 months of age. The study showed a 22% re-
duction (95% conﬁdence interval [CI], −5%–41%) in mortality
before 36 months of age in the intervention group, in the inten-
tion-to-treat analysis. Many children had also been enrolled in a
trial of neonatal vitamin A supplementation (NVAS); among
children not receiving NVAS at birth, early MV receipt was as-
sociated with a 41% reduction (95% CI, 11%–61%) in mortality
between 4.5 and 36 months of age; in children who had received
NVAS, the effect of MV receipt was a 7% higher (95% CI,
−29%–61%) mortality risk [1]. The effect of early MV receipt
was also seen for hospital admission, in which early V receipt
was associated with a signiﬁcant reduction in all-cause hospital-
izations between 4.5 and 9 months of age [8]. This was
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consistent with ﬁndings of another study, which indicated that
MV reduced non–measles-related mortality among hospitalized
children in Guinea-Bissau [9].
We do not know whether early MV receipt also affects the
incidence of less serious morbidities for which children are
not hospitalized. In 2011, when children no longer received
NVAS, the BHP initiated a randomized trial examining the ef-
fect of 2 doses of MV at 18 weeks and 9 months of age (inter-
vention) versus 1 dose of MV at 9 months of age (control). A
substudy was initiated to test whether early MV receipt reduced
general morbidity up to 9 months of age, when all children re-
ceived MV. We also investigated adverse events in connection
with early MV receipt. The results from the substudy are pre-
sented in the present article.
METHODS
Setting and Study Population
The BHP in Guinea-Bissau maintains a health and demograph-
ic surveillance system in the capital, Bissau. The study area cov-
ers 6 districts with around 100 000 inhabitants. Three health
centers in the study area provide routine vaccinations, and
BHP registers all vaccines given to children living in the study
area. A ﬁeld team visits all houses once monthly to record new
pregnancies and births.
Main Trial Design
The main trial was initiated in August 2011. Children were ran-
domly assigned to receive either 2 doses of MV at 18 weeks and
9 months of age (the intervention group) or the recommended
single dose of MV at 9 months of age (the control group). The
BHP identiﬁed all newborn children in the study area and re-
minded the mothers to bring their children for vaccination at
the health centers. Children in Guinea-Bissau receive pentava-
lent vaccine (targeting DTP, hepatitis B, andHaemophilus inﬂu-
enzae type b infection) at 6, 10, and 14 weeks of age [10].
Children between 18 weeks and 7 months of age, who had re-
ceived the third and last dose of pentavalent vaccine at least 4
weeks earlier, were eligible to be enrolled in the trial. NVAS
was not given during the study. There were no reports of circu-
lating measles virus during the trial; the last measles epidemic in
Bissau was in 2003–2004.
When the child was ready to be enrolled, the mother/guard-
ian was invited to come to the health center. At the health cen-
ter, the mother/guardian received an explanation of the study in
the local language, Creole, and a written explanation in the of-
ﬁcial language, Portuguese. Anthropometric measurements of
the child were performed, and a clinical examination conducted
by a physician. Provided the mother agreed to participate, she
was asked to sign or ﬁngerprint a consent form. The mother
then drew a numbered lot from an envelope to randomly assign
the child to the intervention or control group, using block ran-
domization stratiﬁed by sex (block size, 24; randomization ratio,
2:1 for the intervention group to the control group). The vaccine
used was a standard-titer Edmonston-Zagreb MV from the
Serum Institute of India. Placebo was not used, as mothers
may erroneously believe that their child received MV and not
seek MV when their child reached 9 months of age. Children
with physical malformations or with severe malnutrition
(mid-upper-arm circumference, <115 mm) were excluded and
referred for treatment. Overtly sick children were not invited
to participate but, instead, were referred to consultation at the
health center; the mother and her child were invited back for
enrollment once the child had recovered.
Morbidity Substudy Design
The substudy of morbidity was initiated in October 2011, and
the last child was enrolled in June 2013. For logistic reasons, a
maximum of 5 children were enrolled every day; if >5 children
were eligible, the 5 youngest were selected. Children enrolled in
the substudy were followed with weekly morbidity interviews
between enrollment and 9 months of age. Trained ﬁeld assis-
tants who were unaware of the child′s randomization status
conducted interviews with the mother. The ﬁrst weekly visit
with a child took place 6 days after enrollment, and the ﬁeld as-
sistant would explain the purpose and the procedures of the
weekly visits. To give the mother a better understanding of
the symptoms, we gave them a ﬂyer with custom-made illustra-
tions of the symptoms. At the weekly visits, the ﬁeld assistants
asked about the following symptoms during each of the past 7
days (with the day of visit included): diarrhea, vomiting, cough,
lack of appetite, crying more than usual, fever, and convulsions.
Furthermore, the assistant asked whether the mother had taken
the child for consultation or given the child medicine. If any
medication was administered during the past 7 days, the mother
was asked to show the medication, and the type of medication
was recorded. In addition to the interview, on the day of the visit
the assistant registered whether skin reactions, conjunctivitis,
and nasal discharge were present and measured the child’s ax-
illary temperature. If the ﬁeld assistant encountered a sick child,
the child was referred for consultation. If a child had moved
within the BHP catchment area, the ﬁeld assistant would imme-
diately try to visit the new house. Follow-up for a child would
terminate if the child moved outside the study area.
Deﬁnition of Possible Adverse Events
Adverse events associated with MV were deﬁned as fever, con-
vulsions, and skin reactions. Fever may occur around days 5–12
after MV receipt, and the risk of febrile seizures increases
around day 8–14 [11]. Fever was deﬁned as an axillary temper-
ature of >37.0°C. MV-associated adverse events affecting the
skin were deﬁned as generalized exanthema, which occurs
around day 7–10 after vaccination [11]. To have a period in
which most adverse events would be captured, we analyzed ad-
verse events from days 5 to 14.
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Deﬁnition of General Morbidity
We expected that children randomly assigned to the interven-
tion group would have a higher incidence of adverse events in
the ﬁrst 14 days after enrollment in the study [12]. Hence, the
potential NSEs of early MV receipt were assessed from day 15
after enrollment to 9 months of age. Fever was, as in the analyses
on possible adverse events, deﬁned as an axillary temperature of
>37.0°C. Skin reaction was deﬁned as generalized exanthema,
abscess, or localized rash.
Statistical Analyses
Adverse Events
We used log-binominal regression to estimate prevalence ratios
and 95% CIs for potential adverse events in comparisons of the
intervention and control groups.
General Morbidity
Maternally reported and assistant-observed symptoms were an-
alyzed using Cox regression, with time since randomization as
the underlying time, to provide hazard ratios (HRs) with 95%
CIs for comparison of the intervention and control groups.
Use of age as the underlying time did not affect the results.
Data were analyzed as a multiple failure time data set. For ma-
ternally reported symptoms, symptoms were registered daily.
Symptoms extending over consecutive days contributed only
1 episode; if symptoms returned after 1 symptom-free day, it
constituted a new episode. For the weekly observations by the
ﬁeld assistant, multiple events over consecutive visits were treat-
ed as separate events, except for skin reactions, which were
treated as 1 event if multiple episodes were observed. We
made this decision because of the long-lasting character of
skin reactions and, therefore, the higher likelihood that the
manifestation of symptoms in the skin observed during 2 con-
secutive visits constitutes the same episode.
All analyses were stratiﬁed by sex because early MV receipt
may have sex-differential effects [13]. Furthermore, the previous
trials of early MV receipt have shown that mortality is reduced
if MV is administered in the presence of measles virus maternal
antibodies, as compared to vaccination in the absence of mater-
nal antibodies [14]. Children who are younger will have more
antibodies, and we therefore conducted an analysis stratiﬁed
by age at inclusion, using a cutoff of 140 days (20 weeks, or
4.5 months) of age (ie, <20 weeks vs ≥20 weeks).
As prespeciﬁed in the study protocol, we examined whether the
estimated effect of early MV receipt was inﬂuenced by other vac-
cinations. The only vaccination given during follow-up was OPV,
during national campaigns targeting all children present during
the campaign. We subdivided the follow-up time into time before
OPV campaigns and time after OPV campaigns. OPV campaigns
were conducted in November 2011, March 2012, and May 2013.
The ﬁrst analysis, “before OPV campaign,” consisted of follow-up
before the ﬁrst day of OPV campaigns, and the second analysis,
“after OPV campaign,” consisted of follow-up after the OPV
campaigns. Hence, events that occurred during an OPV cam-
paign have not been included in these analyses.
Stata, version 11, was used for the statistical analyses. Data can
be obtained for further analysis through contact with the authors.
Ethical Considerations
The BHP offered free healthcare consultations and essential
drugs to all participants. The Guinean Ministry of Health′s Re-
search Coordination Committee approved the protocol, and we
obtained consultative approval from the Danish Central Ethical
Committee. The study was registered at clinicaltrials.gov
(NCT01486355).
RESULTS
Over a study period of 20 months, 3117 children were eligible
for enrollment into the morbidity subgroup study (Figure 1);
since we could only enroll 5 children per day for the morbidity
study, 1625 were included in this substudy. There were no sig-
niﬁcant differences between the 1625 participants and the 1492
nonparticipants at enrollment, except with regard to age,
weight, and height, which were all lower among participants be-
cause we selectively invited the youngest children if >5 children
were eligible per day (data not shown). In the follow-up period,
3 children were not found at home at any visits, 16 were travel-
ing throughout the follow-up period, 4 had moved before any
follow-up data had been obtained, and forms for 10 were lost.
These children were excluded from the analyses. One child had
received MV elsewhere and was censored on the day they re-
ceived the MV. There were no differences in baseline character-
istics between the intervention and control groups (Table 1).
For all enrolled children, 77% of all attempted follow-up visits
were successful, with the mother/guardian and child found at
home (frequency of successful follow-up, 76% in the interven-
tion group, and 77% in the control group).
Possible Adverse Events Associated With Early MV Receipt
Overall and stratiﬁed by sex, there was no effect of early MV re-
ceipt on possible adverse events (Table 2). As expected, there
was a tendency toward a higher frequency of measured fever
at day 7 among children in the intervention group. However,
for maternally reported fever in children, this tendency was
opposite.
General Morbidity
Maternally Reported Symptoms
Early MV receipt was associated with a lower hazard for diar-
rhea (HR, 0.89; 95% CI, .82–.97), vomiting (HR, 0.86; 95% CI,
.75–.98), and reported fever (HR, 0.93; 95% CI, .87–1.00;
Table 3). The remaining symptoms also tended to be less com-
mon in the intervention group. Stratiﬁed by sex, the beneﬁcial
effect of early MV receipt on morbidity was generally stronger
in boys, compared with girls. Boys who received MV early had a
reduced risk of diarrhea (HR, 0.87; 95% CI, .78–.98), vomiting
(HR, 0.78; 95% CI, .66–.92), coughing (HR, 0.88; 95% CI,
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.80–.98), and reported fever (HR, 0.89; 95% CI, .82–.98; Figure 2
and Supplementary Data), compared with control boys. For
coughing and crying more than normal, there was an interac-
tion between sex and early MV receipt (coughing, P = .02; cry-
ing more than normal, P = .01).
Field Assistant Observations at Home Visit
Early MV receipt was associated with a reduced risk of skin re-
actions (HR, 0.76; 95% CI, .60–.95; Table 3). Stratiﬁed by sex,
early MV receipt was associated with a decreased risk of skin
reactions in boys (HR, 0.59; 95% CI, .43–.81) but not in girls
(HR, 0.99; 95% CI, .71–1.40; Pinteraction = 0.03; Figure 2 and Sup-
plementary Data).
Age at Inclusion
When we stratiﬁed analysis by age at inclusion, children includ-
ed at <20 weeks of age and randomly assigned to the interven-
tion group had lower hazards of coughing (HR, 0.86; 95% CI,
.76–0.97), lack of appetite (HR, 0.74; 95% CI, .59–.93), reported
fever (HR, 0.84; 95% CI, .76–.94), measured fever (HR, 0.74;
Figure 1. Flow of participant through the study. Infants who died between enrollment and 9 months were included in the analyzes, but censored at time of the last visit seen
alive. Abbreviation: MUAC, mid-upper-arm circumference.
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Deﬁnition of General Morbidity
We expected that children randomly assigned to the interven-
tion group would have a higher incidence of adverse events in
the ﬁrst 14 days after enrollment in the study [12]. Hence, the
potential NSEs of early MV receipt were assessed from day 15
after enrollment to 9 months of age. Fever was, as in the analyses
on possible adverse events, deﬁned as an axillary temperature of
>37.0°C. Skin reaction was deﬁned as generalized exanthema,
abscess, or localized rash.
Statistical Analyses
Adverse Events
We used log-binominal regression to estimate prevalence ratios
and 95% CIs for potential adverse events in comparisons of the
intervention and control groups.
General Morbidity
Maternally reported and assistant-observed symptoms were an-
alyzed using Cox regression, with time since randomization as
the underlying time, to provide hazard ratios (HRs) with 95%
CIs for comparison of the intervention and control groups.
Use of age as the underlying time did not affect the results.
Data were analyzed as a multiple failure time data set. For ma-
ternally reported symptoms, symptoms were registered daily.
Symptoms extending over consecutive days contributed only
1 episode; if symptoms returned after 1 symptom-free day, it
constituted a new episode. For the weekly observations by the
ﬁeld assistant, multiple events over consecutive visits were treat-
ed as separate events, except for skin reactions, which were
treated as 1 event if multiple episodes were observed. We
made this decision because of the long-lasting character of
skin reactions and, therefore, the higher likelihood that the
manifestation of symptoms in the skin observed during 2 con-
secutive visits constitutes the same episode.
All analyses were stratiﬁed by sex because early MV receipt
may have sex-differential effects [13]. Furthermore, the previous
trials of early MV receipt have shown that mortality is reduced
if MV is administered in the presence of measles virus maternal
antibodies, as compared to vaccination in the absence of mater-
nal antibodies [14]. Children who are younger will have more
antibodies, and we therefore conducted an analysis stratiﬁed
by age at inclusion, using a cutoff of 140 days (20 weeks, or
4.5 months) of age (ie, <20 weeks vs ≥20 weeks).
As prespeciﬁed in the study protocol, we examined whether the
estimated effect of early MV receipt was inﬂuenced by other vac-
cinations. The only vaccination given during follow-up was OPV,
during national campaigns targeting all children present during
the campaign. We subdivided the follow-up time into time before
OPV campaigns and time after OPV campaigns. OPV campaigns
were conducted in November 2011, March 2012, and May 2013.
The ﬁrst analysis, “before OPV campaign,” consisted of follow-up
before the ﬁrst day of OPV campaigns, and the second analysis,
“after OPV campaign,” consisted of follow-up after the OPV
campaigns. Hence, events that occurred during an OPV cam-
paign have not been included in these analyses.
Stata, version 11, was used for the statistical analyses. Data can
be obtained for further analysis through contact with the authors.
Ethical Considerations
The BHP offered free healthcare consultations and essential
drugs to all participants. The Guinean Ministry of Health′s Re-
search Coordination Committee approved the protocol, and we
obtained consultative approval from the Danish Central Ethical
Committee. The study was registered at clinicaltrials.gov
(NCT01486355).
RESULTS
Over a study period of 20 months, 3117 children were eligible
for enrollment into the morbidity subgroup study (Figure 1);
since we could only enroll 5 children per day for the morbidity
study, 1625 were included in this substudy. There were no sig-
niﬁcant differences between the 1625 participants and the 1492
nonparticipants at enrollment, except with regard to age,
weight, and height, which were all lower among participants be-
cause we selectively invited the youngest children if >5 children
were eligible per day (data not shown). In the follow-up period,
3 children were not found at home at any visits, 16 were travel-
ing throughout the follow-up period, 4 had moved before any
follow-up data had been obtained, and forms for 10 were lost.
These children were excluded from the analyses. One child had
received MV elsewhere and was censored on the day they re-
ceived the MV. There were no differences in baseline character-
istics between the intervention and control groups (Table 1).
For all enrolled children, 77% of all attempted follow-up visits
were successful, with the mother/guardian and child found at
home (frequency of successful follow-up, 76% in the interven-
tion group, and 77% in the control group).
Possible Adverse Events Associated With Early MV Receipt
Overall and stratiﬁed by sex, there was no effect of early MV re-
ceipt on possible adverse events (Table 2). As expected, there
was a tendency toward a higher frequency of measured fever
at day 7 among children in the intervention group. However,
for maternally reported fever in children, this tendency was
opposite.
General Morbidity
Maternally Reported Symptoms
Early MV receipt was associated with a lower hazard for diar-
rhea (HR, 0.89; 95% CI, .82–.97), vomiting (HR, 0.86; 95% CI,
.75–.98), and reported fever (HR, 0.93; 95% CI, .87–1.00;
Table 3). The remaining symptoms also tended to be less com-
mon in the intervention group. Stratiﬁed by sex, the beneﬁcial
effect of early MV receipt on morbidity was generally stronger
in boys, compared with girls. Boys who received MV early had a
reduced risk of diarrhea (HR, 0.87; 95% CI, .78–.98), vomiting
(HR, 0.78; 95% CI, .66–.92), coughing (HR, 0.88; 95% CI,
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.80–.98), and reported fever (HR, 0.89; 95% CI, .82–.98; Figure 2
and Supplementary Data), compared with control boys. For
coughing and crying more than normal, there was an interac-
tion between sex and early MV receipt (coughing, P = .02; cry-
ing more than normal, P = .01).
Field Assistant Observations at Home Visit
Early MV receipt was associated with a reduced risk of skin re-
actions (HR, 0.76; 95% CI, .60–.95; Table 3). Stratiﬁed by sex,
early MV receipt was associated with a decreased risk of skin
reactions in boys (HR, 0.59; 95% CI, .43–.81) but not in girls
(HR, 0.99; 95% CI, .71–1.40; Pinteraction = 0.03; Figure 2 and Sup-
plementary Data).
Age at Inclusion
When we stratiﬁed analysis by age at inclusion, children includ-
ed at <20 weeks of age and randomly assigned to the interven-
tion group had lower hazards of coughing (HR, 0.86; 95% CI,
.76–0.97), lack of appetite (HR, 0.74; 95% CI, .59–.93), reported
fever (HR, 0.84; 95% CI, .76–.94), measured fever (HR, 0.74;
Figure 1. Flow of participant through the study. Infants who died between enrollment and 9 months were included in the analyzes, but censored at time of the last visit seen
alive. Abbreviation: MUAC, mid-upper-arm circumference.
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95% CI, .60–.89), and crying more than normal (HR, 0.74; 95%
CI, .61–.89), compared with children in the control group. For
each of these symptoms, we found a signiﬁcant interaction
(P < .05) between age at inclusion and early MV receipt. The re-
verse tendency, with early MV receipt being associated with a
lower risk for children included at ≥20 weeks of age, was seen
for diarrhea (HR, 0.83; 95% CI, .75–.93) and vomiting (HR,
0.83; 95% CI, .71–.98); for diarrhea, this resulted in a signiﬁcant
interaction between age and early MV receipt (Figure 3 and
Supplementary Data).
Effect Modiﬁcation by OPV Campaigns
We subdivided the follow-up time into time before OPV cam-
paigns and time after OPV campaigns and found a signiﬁcantly
reduced risk of maternally reported diarrhea and vomiting in
the group that received MV early, before OPV campaigns.
There was no signiﬁcant effect modiﬁcation by OPV campaign,
however, for any of the outcomes (Supplementary Figure 1 and
Supplementary Data).
DISCUSSION
We did not ﬁnd statistically signiﬁcant differences between the 2
randomized groups when looking at possible adverse events.
We found a reduced risk of maternally reported and assistant-
observed morbidity in the intervention group. The beneﬁcial ef-
fect of early MV receipt was stronger in boys, compared with
girls, and tended to be stronger in the youngest group of
children.
For logistic reasons, we were only able to include 5 children
per day. Therefore participants differed from nonparticipants
with respect to age, weight, and height, but otherwise there
were no differences between participants and nonparticipants.
All background factors were evenly distributed between the in-
tervention and control groups. The follow-up was based on data
from home visits, and the loss to follow-up was limited. Fur-
thermore, the assistants were trained in a uniform way by the
same supervisor, with regard to both interview technique and
health observations. We did not use placebo. However, early
MV receipt was not registered on the health card, and the
ﬁeld assistants were not aware of the randomization status,
nor were the physicians or nurses conducting consultations
and prescribing medicine. The mothers of the enrolled children
were not blinded, which could have led to a bias in the reporting
of symptoms. However, the results for consultation and use of
medicine and the symptoms observed by the ﬁeld assistants
were in the same direction, supporting that the maternally re-
ported symptoms were not due to the mothers′ awareness of
the randomization status.
The study reported 12 primary analyses and 36 secondary
analyses of an effect of early MV receipt on morbidity, entailing
a risk of chance ﬁndings. The results should therefore be inter-
preted with this in mind.
There was no circulating measles virus in Bissau in the pre-
ceding 2–3 years; the last measles epidemic in Bissau was in
2003–2004 [1]. During the study, we had a system of measles
surveillance, consisting of ﬁeld assistants going to all houses
once monthly to ask for measles cases, as well as daily reporting
of potential measles cases from the health centers and the main
hospital of Bissau. No measles case was found in the study area
during the study, and we therefore believe the beneﬁcial effect of
early MV receipt on morbidity is due to NSEs, contradicting a
recent hypothesis suggesting that the beneﬁcial effects of MV
are due to its prevention of measles-associated immunological
memory loss [15].
The WHO recently reviewed the potential NSEs of vaccines
in both observational and randomized trials. It concluded that
there was evidence that MV reduced the risk of all-cause mor-
tality independently of its effect on measles-attributable mortal-
ity [16]. The present trial corroborates the results of the WHO
review by ﬁnding a beneﬁcial effect of early MV receipt on mor-
bidity. Furthermore, in the previous trial of early MV receipt,
early receipt at 4.5 months of age reduced the risk of hospital-
izations for respiratory infections between 4.5 and 9 months of
age, compared with the group receiving MV only at 9 months of
age [8]. Likewise, a study from the pediatric ward in Guinea-
Bissau showed that receipt of MV reduced the risk of death
from pneumonia [9].
A Danish study recently analyzed the effect on hospital ad-
missions of having the measles-mumps-rubella vaccine
(MMR) as compared to the inactivated DTP (ie, DTaP)/
Table 1. Baseline Characteristics of Children Enrolled in the Morbidity
Subgroup Study and Randomly Assigned to Receive (Intervention) or Not
Receive (Control) an Early Dose of Measles Vaccine at 18 Weeks of Age
Characteristic
Intervention
(n = 1068)
Control
(n = 557)
Sociodemographic
Age at enrollment, wk 21.1 (19.7–21.7) 21.1 (19.7–21.7)
Age of mother at enrollment, y 26 (21–30) 26 (22–30)
Male sex 53 (563) 53 (295)
Living in Bandim district 42 (447) 45 (249)
Toilet inside house 22 (235) 23 (130)
Anthropometry
Weight, kg, mean ± SD 7.2 ± 1.0 7.2 ± 1.0
Height, cm, mean ± SD 63.2 ± 2.5 63.2 ± 2.5
MUAC, mm, mean ± SD 141 ± 12 142 ± 11
Maternal MUAC, mm, mean ± SD 280 ± 38 281 ± 36
Morbidity
Diarrhea at enrollment 9 (97) 12 (66)
Coughing at enrollment 32 (338) 34 (191)
Hospitalized before enrollment 5 (54) 5 (30)
Risk factor at enrollment
No. of people/bed 2.8 (2–3) 2.9 (2–3)
No. of people/sleeping room 4.3 (3–5) 4.2 (3–5)
Data are % (no.) of subjects or mean value (interquartile range), unless otherwise indicated.
Abbreviation: MUAC, mid-upper-arm circumference.
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95% CI, .60–.89), and crying more than normal (HR, 0.74; 95%
CI, .61–.89), compared with children in the control group. For
each of these symptoms, we found a signiﬁcant interaction
(P < .05) between age at inclusion and early MV receipt. The re-
verse tendency, with early MV receipt being associated with a
lower risk for children included at ≥20 weeks of age, was seen
for diarrhea (HR, 0.83; 95% CI, .75–.93) and vomiting (HR,
0.83; 95% CI, .71–.98); for diarrhea, this resulted in a signiﬁcant
interaction between age and early MV receipt (Figure 3 and
Supplementary Data).
Effect Modiﬁcation by OPV Campaigns
We subdivided the follow-up time into time before OPV cam-
paigns and time after OPV campaigns and found a signiﬁcantly
reduced risk of maternally reported diarrhea and vomiting in
the group that received MV early, before OPV campaigns.
There was no signiﬁcant effect modiﬁcation by OPV campaign,
however, for any of the outcomes (Supplementary Figure 1 and
Supplementary Data).
DISCUSSION
We did not ﬁnd statistically signiﬁcant differences between the 2
randomized groups when looking at possible adverse events.
We found a reduced risk of maternally reported and assistant-
observed morbidity in the intervention group. The beneﬁcial ef-
fect of early MV receipt was stronger in boys, compared with
girls, and tended to be stronger in the youngest group of
children.
For logistic reasons, we were only able to include 5 children
per day. Therefore participants differed from nonparticipants
with respect to age, weight, and height, but otherwise there
were no differences between participants and nonparticipants.
All background factors were evenly distributed between the in-
tervention and control groups. The follow-up was based on data
from home visits, and the loss to follow-up was limited. Fur-
thermore, the assistants were trained in a uniform way by the
same supervisor, with regard to both interview technique and
health observations. We did not use placebo. However, early
MV receipt was not registered on the health card, and the
ﬁeld assistants were not aware of the randomization status,
nor were the physicians or nurses conducting consultations
and prescribing medicine. The mothers of the enrolled children
were not blinded, which could have led to a bias in the reporting
of symptoms. However, the results for consultation and use of
medicine and the symptoms observed by the ﬁeld assistants
were in the same direction, supporting that the maternally re-
ported symptoms were not due to the mothers′ awareness of
the randomization status.
The study reported 12 primary analyses and 36 secondary
analyses of an effect of early MV receipt on morbidity, entailing
a risk of chance ﬁndings. The results should therefore be inter-
preted with this in mind.
There was no circulating measles virus in Bissau in the pre-
ceding 2–3 years; the last measles epidemic in Bissau was in
2003–2004 [1]. During the study, we had a system of measles
surveillance, consisting of ﬁeld assistants going to all houses
once monthly to ask for measles cases, as well as daily reporting
of potential measles cases from the health centers and the main
hospital of Bissau. No measles case was found in the study area
during the study, and we therefore believe the beneﬁcial effect of
early MV receipt on morbidity is due to NSEs, contradicting a
recent hypothesis suggesting that the beneﬁcial effects of MV
are due to its prevention of measles-associated immunological
memory loss [15].
The WHO recently reviewed the potential NSEs of vaccines
in both observational and randomized trials. It concluded that
there was evidence that MV reduced the risk of all-cause mor-
tality independently of its effect on measles-attributable mortal-
ity [16]. The present trial corroborates the results of the WHO
review by ﬁnding a beneﬁcial effect of early MV receipt on mor-
bidity. Furthermore, in the previous trial of early MV receipt,
early receipt at 4.5 months of age reduced the risk of hospital-
izations for respiratory infections between 4.5 and 9 months of
age, compared with the group receiving MV only at 9 months of
age [8]. Likewise, a study from the pediatric ward in Guinea-
Bissau showed that receipt of MV reduced the risk of death
from pneumonia [9].
A Danish study recently analyzed the effect on hospital ad-
missions of having the measles-mumps-rubella vaccine
(MMR) as compared to the inactivated DTP (ie, DTaP)/
Table 1. Baseline Characteristics of Children Enrolled in the Morbidity
Subgroup Study and Randomly Assigned to Receive (Intervention) or Not
Receive (Control) an Early Dose of Measles Vaccine at 18 Weeks of Age
Characteristic
Intervention
(n = 1068)
Control
(n = 557)
Sociodemographic
Age at enrollment, wk 21.1 (19.7–21.7) 21.1 (19.7–21.7)
Age of mother at enrollment, y 26 (21–30) 26 (22–30)
Male sex 53 (563) 53 (295)
Living in Bandim district 42 (447) 45 (249)
Toilet inside house 22 (235) 23 (130)
Anthropometry
Weight, kg, mean ± SD 7.2 ± 1.0 7.2 ± 1.0
Height, cm, mean ± SD 63.2 ± 2.5 63.2 ± 2.5
MUAC, mm, mean ± SD 141 ± 12 142 ± 11
Maternal MUAC, mm, mean ± SD 280 ± 38 281 ± 36
Morbidity
Diarrhea at enrollment 9 (97) 12 (66)
Coughing at enrollment 32 (338) 34 (191)
Hospitalized before enrollment 5 (54) 5 (30)
Risk factor at enrollment
No. of people/bed 2.8 (2–3) 2.9 (2–3)
No. of people/sleeping room 4.3 (3–5) 4.2 (3–5)
Data are % (no.) of subjects or mean value (interquartile range), unless otherwise indicated.
Abbreviation: MUAC, mid-upper-arm circumference.
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inactivated polio/H. inﬂuenzae type b vaccine as the latest vac-
cine. The study found a reduced risk of admissions for all types
of infection when MMR was the latest vaccine received, and
particularly so for lower respiratory tract infections [17]. This
is consistent with the present study, in which we found a
Table 3. Effect of Early Measles Vaccine Receipt on Maternally Reported and Assistant-Observed Morbidity After Random Assignment to Receive
(Intervention) or Not Receive (Control) an Early Dose of Measles Vaccine
Variable
Morbidity Rate (No. of Events/Person-Years of Observation)
Hazard Ratioa (95% CI)Intervention (n = 1048) Control (n = 544)
Maternally reported morbidity
Diarrhea 6.0 (1397/233) 6.7 (805/120) 0.89b (.82–.97)
Vomiting 2.5 (598/241) 2.9 (358/124) 0.86b (.75–.98)
Coughing 9.4 (1929/206) 9.7 (1018/105) 0.96 (.89–1.04)
Lack of appetite 2.2 (525/236) 2.4 (290/121) 0.93 (.80–1.07)
Crying more than normal 3.5 (820/237) 3.5 (431/122) 0.98 (.87–1.10)
Reported fever 10.1 (2316/228) 10.9 (1273/117) 0.93b (.87–1.00)
Reported consultations 4.4 (1080/244) 4.4 (557/126) 1.00 (.90–1.11)
Reported use of medicine 8.8 (1894/214) 9.2 (1017/110) 0.96 (.89–1.04)
Assistant-observed morbidity
Skin reactionc 5.5 (185/34) 7.1 (124/18) 0.76b (.60–.95)
Conjunctivitis 4.6 (156/34) 4.1 (72/18) 1.13 (.86–1.49)
Nasal discharge 93.1 (3171/34) 96.1 (1686/18) 0.97 (.91–1.03)
Measured fever 19.4 (662/34) 21.7 (381/18) 0.90 (.79–1.02)
Events occurring from day 15 after random assignment through 9 months of age were included in the analysis. Maternally reported symptoms were registered per day. Symptoms extending
over consecutive days contributed only 1 episode, and the person-years reported in the table are therefore symptom specific.
Abbreviation: CI, confidence interval.
a Determined using Cox regression, with time since randomization as the underlying time.
b P < .05 for the comparison between the intervention and control groups.
c Defined as generalized exanthema (n = 139 events), abscess (n = 70 events), or localized rash (n = 100 events).
Figure 2. The effect of early measles vaccine receipt (intervention) on maternally
reported and assistant-observed morbidity, stratified by sex. Hazard ratios (HRs) with
95% confidence intervals (CIs; whiskers) for maternally reported and assistant-ob-
served morbidity were determined using Cox regression, with time since randomi-
zation as the underlying time, to compare the intervention group to the group that did
not receive an early dose of measles vaccine (control). For maternally reported symp-
toms, symptoms were registered per day. Symptoms extending over consecutive
days contributed only 1 episode. *P < .05 for comparison of the intervention and con-
trol groups; **P < .05 for interaction between sex and early measles vaccine receipt.
Figure 3. The effect of early measles vaccine receipt (intervention) on maternally
reported and assistant-observed morbidity, stratified by age at inclusion. Hazard ra-
tios (HRs) with 95% confidence intervals (CIs; whiskers) for maternally reported and
assistant-observed morbidity were determined using Cox regression, with time since
randomization as the underlying time, to compare the intervention group to the group
that did not receive an early dose of measles vaccine (control). For maternally report-
ed symptoms, symptoms were registered per day. Symptoms extending over consec-
utive days contributed only 1 episode. *P < .05 for comparison of the intervention
and control groups; **P < .05 for interaction between age at enrollment and early
measles vaccine receipt.
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reduced risk of fever and a tendency toward a reduced risk of
coughing, which reached signiﬁcance in males and in children
enrolled before 20 weeks of age. In line with our ﬁndings of re-
duced risks of diarrhea and vomiting, the Danish study [17] also
found a reduced risk of admissions for gastrointestinal infec-
tions. It should be noted that these studies of the NSEs of
MV/MMR have mainly compared MV recipients to children
for whom DTP-containing vaccine was the most recent vaccine
received. Because DTP-containing vaccine has been associated
with increased overall mortality and morbidity [5, 17], it cannot
be excluded that the observed beneﬁcial effect of MV is partly a
consequence of an excess mortality and morbidity in the DTP-
vaccinated control group.
We found a tendency toward a stronger beneﬁcial effect in
boys as compared to girls. These sex-differential effects are in-
consistent with previous observations, in which girls beneﬁtted
more from MV [1, 8, 13, 18]. However, we have previously
shown that there is a beneﬁt from receiving MV in the presence
of maternal antibody [14]. We have also previously shown that
girls lose maternal antibodies faster than boys [19]; as more and
more mothers are vaccinated and children receive less maternal
measles antibody, girls would be most affected. Hence, this
could potentially explain why the boys beneﬁtted more in the
present study than in previous studies.
In line with the literature on adverse events after MV receipt, we
found an increased risk of measured fever among children in the
intervention group during the 2 weeks after immunization [11].
Little is known about the immunological mechanisms behind
the NSEs of MV. The observation that vaccines modify the im-
munological response to nonrelated pathogens is documented
for BCG, which increases the innate responsiveness via epige-
netic reprogramming of monocytes [20]. Whether MV acts
via a similar mechanism is not known. The limited data avail-
able on the nonspeciﬁc immune activation of MV are somewhat
conﬂicting, as studies indicate that MV transiently decreases
[21–23] or increases [24, 25] the response potential of lympho-
cytes. Some studies indicate that MV skews immune reactions
toward a T-helper type 1–biased proﬁle in infants [21, 24],
which may affect responses to subsequent pathogens and vac-
cines. Moreover, MV may carry cross-reactive epitopes poten-
tially conferring immunity to heterologous pathogens,
including respiratory syncytial virus (RSV) [26], a prominent
cause of infections in the present study population [27]. To
that end, the observed reduction in fever and coughing may
be related to reduced incidence or severity of RSV infection,
as also suggested in a study of hospital contacts among young
Danish children [28].
To our knowledge, this is the ﬁrst study to examine continu-
ous subsequent morbidity after receiving an MV dose earlier
than recommended. The outcomes of the present study indicate
a decreased hazard of morbidity after early MV receipt, at 18
weeks of age, and add to the existing evidence supporting that
an early 2-dose MV strategy has beneﬁcial NSEs. Although the
WHO recommends a 2-dose vaccination strategy for MV for all
national immunization programs, 9 months is the recommend-
ed age for the ﬁrst dose, and 15–18 months is the age recom-
mended for the second dose [29]. In countries with low rates
of measles, the ﬁrst dose may be administered even later than
9 months. However, based on the current evidence, it seems
that recommending a standard dose of MV at 18 weeks of age
could decrease mortality and morbidity in a low-income setting
such as Guinea-Bissau.
Supplementary Data
Supplementary materials are available at http://jid.oxfordjournals.org.
Consisting of data provided by the author to beneﬁt the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
Notes
Acknowledgments. The research group thanks the mothers and chil-
dren participating in the trial. We thank the staff at Bandim Health Project,
the partners at the health centers in the study area, and, for supervising the
statistical analyses, Andreas Andersen.
C. S. B., P. A., and C. M. were the chief investigators of the main measles
trial. V. A. D., S. B. S., A. B. F., C. S. B., and P. A. designed the morbidity
substudy. V. A. D. and S. B. S. initiated the study routines. V. A. D. was re-
sponsible for the recruitment and follow-up for participants, with help from
S. B. S., S. M. R., and C. B. performed all health assessments at enrollment in
the main trial. Enrollment and procedures of the main trial were supervised
by V. A. D., S. B. S., S. M. R., A. B. F., L. D. C., and V. A. D. was responsible
for the statistical analyses, with help from S. B. S. and A. B. F. All authors
contributed to and approved the ﬁnal version of the article.
Disclaimer. The funding agencies had no role in the study design, data
collection, data analysis, data interpretation, or the writing of the
manuscript.
Financial support. This work was supported by the Augustinus Foun-
dation; the Lundbeck Foundation; the Dagmar Marshall Foundation; the
Danish Council of Independent Research; the Danish Ministry of Higher
Education and Science (DFF-1333-00192); the Søren Segel and Johanne
Wilbroe Segel Research Foundation; the European Research Council
(ERC-2009-StG to C. S. B.; grant 243149 in support of the main trial);
the Danish National Research Foundation (grant DNRF108 in support of
the main trial); the Danish Council for Development Research, Ministry
of Foreign Affairs (grant 104.Dan.8.f. in support of investigations of non-
speciﬁc effects of vaccines), the Novo Nordisk Foundation (in support of
nonspeciﬁc effects of vaccines), and European Union FP7 support for OP-
TIMUNISE (grant Health-F3-2011-261375 in support of nonspeciﬁc effects
of vaccines).
Potential conﬂicts of interests. All authors: No reported conﬂicts. All
authors have submitted the ICMJE Form for Disclosure of Potential Con-
ﬂicts of Interest. Conﬂicts that the editors consider relevant to the content
of the manuscript have been disclosed.
References
1. Aaby P, Martins C, Garly ML, et al. Non-speciﬁc effects of standard measles vac-
cine at 4.5 and 9 months of age on childhood mortality: randomised controlled
trial. BMJ 2010; 341:c6495–c.
2. Aaby P, Bhuiya A, Nahar L, Knudsen K, de Francisco A, Strong M. The survival
beneﬁt of measles immunization may not be explained entirely by the prevention
of measles disease: a community study from rural Bangladesh. Int J Epidemiol
2003; 32:106–16.
3. Aaby P, Samb B, Andersen M, Simondon F. No long-term excess mortality after
measles infection: a community study from Senegal. Am J Epidemiol 1996;
143:1035–41.
4. Lund N, Andersen A, Hansen AS, et al. The effect of oral polio vaccine at birth on
infant mortality: a randomized trial. Clin Infect Dis 2015; 61:1504–11.
8 • JID • Do et al
Early Measles Vaccine Receipt and Morbidity • JID 2017:215 (15 April) • 1195
inactivated polio/H. inﬂuenzae type b vaccine as the latest vac-
cine. The study found a reduced risk of admissions for all types
of infection when MMR was the latest vaccine received, and
particularly so for lower respiratory tract infections [17]. This
is consistent with the present study, in which we found a
Table 3. Effect of Early Measles Vaccine Receipt on Maternally Reported and Assistant-Observed Morbidity After Random Assignment to Receive
(Intervention) or Not Receive (Control) an Early Dose of Measles Vaccine
Variable
Morbidity Rate (No. of Events/Person-Years of Observation)
Hazard Ratioa (95% CI)Intervention (n = 1048) Control (n = 544)
Maternally reported morbidity
Diarrhea 6.0 (1397/233) 6.7 (805/120) 0.89b (.82–.97)
Vomiting 2.5 (598/241) 2.9 (358/124) 0.86b (.75–.98)
Coughing 9.4 (1929/206) 9.7 (1018/105) 0.96 (.89–1.04)
Lack of appetite 2.2 (525/236) 2.4 (290/121) 0.93 (.80–1.07)
Crying more than normal 3.5 (820/237) 3.5 (431/122) 0.98 (.87–1.10)
Reported fever 10.1 (2316/228) 10.9 (1273/117) 0.93b (.87–1.00)
Reported consultations 4.4 (1080/244) 4.4 (557/126) 1.00 (.90–1.11)
Reported use of medicine 8.8 (1894/214) 9.2 (1017/110) 0.96 (.89–1.04)
Assistant-observed morbidity
Skin reactionc 5.5 (185/34) 7.1 (124/18) 0.76b (.60–.95)
Conjunctivitis 4.6 (156/34) 4.1 (72/18) 1.13 (.86–1.49)
Nasal discharge 93.1 (3171/34) 96.1 (1686/18) 0.97 (.91–1.03)
Measured fever 19.4 (662/34) 21.7 (381/18) 0.90 (.79–1.02)
Events occurring from day 15 after random assignment through 9 months of age were included in the analysis. Maternally reported symptoms were registered per day. Symptoms extending
over consecutive days contributed only 1 episode, and the person-years reported in the table are therefore symptom specific.
Abbreviation: CI, confidence interval.
a Determined using Cox regression, with time since randomization as the underlying time.
b P < .05 for the comparison between the intervention and control groups.
c Defined as generalized exanthema (n = 139 events), abscess (n = 70 events), or localized rash (n = 100 events).
Figure 2. The effect of early measles vaccine receipt (intervention) on maternally
reported and assistant-observed morbidity, stratified by sex. Hazard ratios (HRs) with
95% confidence intervals (CIs; whiskers) for maternally reported and assistant-ob-
served morbidity were determined using Cox regression, with time since randomi-
zation as the underlying time, to compare the intervention group to the group that did
not receive an early dose of measles vaccine (control). For maternally reported symp-
toms, symptoms were registered per day. Symptoms extending over consecutive
days contributed only 1 episode. *P < .05 for comparison of the intervention and con-
trol groups; **P < .05 for interaction between sex and early measles vaccine receipt.
Figure 3. The effect of early measles vaccine receipt (intervention) on maternally
reported and assistant-observed morbidity, stratified by age at inclusion. Hazard ra-
tios (HRs) with 95% confidence intervals (CIs; whiskers) for maternally reported and
assistant-observed morbidity were determined using Cox regression, with time since
randomization as the underlying time, to compare the intervention group to the group
that did not receive an early dose of measles vaccine (control). For maternally report-
ed symptoms, symptoms were registered per day. Symptoms extending over consec-
utive days contributed only 1 episode. *P < .05 for comparison of the intervention
and control groups; **P < .05 for interaction between age at enrollment and early
measles vaccine receipt.
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reduced risk of fever and a tendency toward a reduced risk of
coughing, which reached signiﬁcance in males and in children
enrolled before 20 weeks of age. In line with our ﬁndings of re-
duced risks of diarrhea and vomiting, the Danish study [17] also
found a reduced risk of admissions for gastrointestinal infec-
tions. It should be noted that these studies of the NSEs of
MV/MMR have mainly compared MV recipients to children
for whom DTP-containing vaccine was the most recent vaccine
received. Because DTP-containing vaccine has been associated
with increased overall mortality and morbidity [5, 17], it cannot
be excluded that the observed beneﬁcial effect of MV is partly a
consequence of an excess mortality and morbidity in the DTP-
vaccinated control group.
We found a tendency toward a stronger beneﬁcial effect in
boys as compared to girls. These sex-differential effects are in-
consistent with previous observations, in which girls beneﬁtted
more from MV [1, 8, 13, 18]. However, we have previously
shown that there is a beneﬁt from receiving MV in the presence
of maternal antibody [14]. We have also previously shown that
girls lose maternal antibodies faster than boys [19]; as more and
more mothers are vaccinated and children receive less maternal
measles antibody, girls would be most affected. Hence, this
could potentially explain why the boys beneﬁtted more in the
present study than in previous studies.
In line with the literature on adverse events after MV receipt, we
found an increased risk of measured fever among children in the
intervention group during the 2 weeks after immunization [11].
Little is known about the immunological mechanisms behind
the NSEs of MV. The observation that vaccines modify the im-
munological response to nonrelated pathogens is documented
for BCG, which increases the innate responsiveness via epige-
netic reprogramming of monocytes [20]. Whether MV acts
via a similar mechanism is not known. The limited data avail-
able on the nonspeciﬁc immune activation of MV are somewhat
conﬂicting, as studies indicate that MV transiently decreases
[21–23] or increases [24, 25] the response potential of lympho-
cytes. Some studies indicate that MV skews immune reactions
toward a T-helper type 1–biased proﬁle in infants [21, 24],
which may affect responses to subsequent pathogens and vac-
cines. Moreover, MV may carry cross-reactive epitopes poten-
tially conferring immunity to heterologous pathogens,
including respiratory syncytial virus (RSV) [26], a prominent
cause of infections in the present study population [27]. To
that end, the observed reduction in fever and coughing may
be related to reduced incidence or severity of RSV infection,
as also suggested in a study of hospital contacts among young
Danish children [28].
To our knowledge, this is the ﬁrst study to examine continu-
ous subsequent morbidity after receiving an MV dose earlier
than recommended. The outcomes of the present study indicate
a decreased hazard of morbidity after early MV receipt, at 18
weeks of age, and add to the existing evidence supporting that
an early 2-dose MV strategy has beneﬁcial NSEs. Although the
WHO recommends a 2-dose vaccination strategy for MV for all
national immunization programs, 9 months is the recommend-
ed age for the ﬁrst dose, and 15–18 months is the age recom-
mended for the second dose [29]. In countries with low rates
of measles, the ﬁrst dose may be administered even later than
9 months. However, based on the current evidence, it seems
that recommending a standard dose of MV at 18 weeks of age
could decrease mortality and morbidity in a low-income setting
such as Guinea-Bissau.
Supplementary Data
Supplementary materials are available at http://jid.oxfordjournals.org.
Consisting of data provided by the author to beneﬁt the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
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